JP5607719B2 - 代謝プロファイル - Google Patents

代謝プロファイル Download PDF

Info

Publication number
JP5607719B2
JP5607719B2 JP2012501376A JP2012501376A JP5607719B2 JP 5607719 B2 JP5607719 B2 JP 5607719B2 JP 2012501376 A JP2012501376 A JP 2012501376A JP 2012501376 A JP2012501376 A JP 2012501376A JP 5607719 B2 JP5607719 B2 JP 5607719B2
Authority
JP
Japan
Prior art keywords
subject
endogenous
biological sample
metabolites
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012501376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521551A5 (https=
JP2012521551A (ja
Inventor
エリク トルビョルン ルンドステット
ニルス ヨハン トリグ
ヨン ロベルト ガブリエルソン
グニラ エクストリューム
Original Assignee
アナマル アクチボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0905090A external-priority patent/GB0905090D0/en
Priority claimed from GB0905096A external-priority patent/GB0905096D0/en
Priority claimed from GB0905098A external-priority patent/GB0905098D0/en
Application filed by アナマル アクチボラゲット filed Critical アナマル アクチボラゲット
Publication of JP2012521551A publication Critical patent/JP2012521551A/ja
Publication of JP2012521551A5 publication Critical patent/JP2012521551A5/ja
Application granted granted Critical
Publication of JP5607719B2 publication Critical patent/JP5607719B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2012501376A 2009-03-24 2010-03-24 代謝プロファイル Expired - Fee Related JP5607719B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0905096.4 2009-03-24
GB0905090.7 2009-03-24
GB0905090A GB0905090D0 (en) 2009-03-24 2009-03-24 Biomarkers
GB0905096A GB0905096D0 (en) 2009-03-24 2009-03-24 Biomarkers
GB0905098.0 2009-03-24
GB0905098A GB0905098D0 (en) 2009-03-24 2009-03-24 Use of biomarkers
PCT/GB2010/000557 WO2010109192A1 (en) 2009-03-24 2010-03-24 Metabolic profiles

Publications (3)

Publication Number Publication Date
JP2012521551A JP2012521551A (ja) 2012-09-13
JP2012521551A5 JP2012521551A5 (https=) 2013-05-09
JP5607719B2 true JP5607719B2 (ja) 2014-10-15

Family

ID=42228305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501376A Expired - Fee Related JP5607719B2 (ja) 2009-03-24 2010-03-24 代謝プロファイル

Country Status (6)

Country Link
US (2) US20120108668A1 (https=)
EP (1) EP2411812B1 (https=)
JP (1) JP5607719B2 (https=)
ES (1) ES2432534T3 (https=)
GB (1) GB2470803A (https=)
WO (1) WO2010109192A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012868A1 (en) * 2009-07-31 2011-02-03 Anamar Ab Compounds for treatment of inflammation
JP6198377B2 (ja) * 2012-09-14 2017-09-20 キヤノン株式会社 表示制御装置、表示制御方法、及びプログラム
US20160061812A1 (en) * 2013-03-15 2016-03-03 The University Of Birmingham Diagnosis and Treatment of Arthritic Conditions
CN103675181A (zh) * 2013-12-05 2014-03-26 陈东 气相色谱-质谱检测细胞内外液中有机酸、氨基酸、糖的方法
CN106175684B (zh) * 2016-07-13 2018-12-21 华南师范大学 基于激光光谱技术的人体股骨头病变早期诊断设备及其操作方法
CN109115905A (zh) * 2018-07-31 2019-01-01 苏州旭辉检测有限公司 一种血液样本中鸟氨酸的检测方法
CN111307792A (zh) * 2020-02-20 2020-06-19 江苏大学 一种猪肉食源性致病菌挥发性代谢物的色敏仿生传感检测方法
GB202102105D0 (en) * 2021-02-15 2021-03-31 Novabiotics Ltd Prognostic method
CN115290797A (zh) * 2022-09-13 2022-11-04 贵州医科大学 基于气质联用技术的黑骨藤抗类风湿性关节炎代谢组学研究方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
JP4717810B2 (ja) 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド １型糖尿病と２型糖尿病を識別するためのバイオマーカー
US7700364B2 (en) * 2004-10-12 2010-04-20 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
US20070026458A1 (en) 2004-12-17 2007-02-01 Entelos, Inc. Assessing insulin resistance using biomarkers
EP2369346B1 (en) 2006-03-24 2014-08-27 Metanomics GmbH Method for diagnosing diabetes type II
DE102006026173A1 (de) 2006-06-06 2007-12-20 Fachhochschule Südwestfalen Verfahren zur nichtinvasiven Diagnose von Diabetes
AU2007298649B2 (en) 2006-07-28 2012-08-09 Al-Saqqaf, Lamya Prediction and prophylactic treatment of type 1 diabetes
CN101529248A (zh) 2006-09-14 2009-09-09 佐拉生物科学有限公司 作为用于早期预测自身免疫和1型糖尿病风险之工具的生物流体代谢物谱分析
EP3067692B1 (en) * 2007-06-29 2019-04-17 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry (lc-ms)

Also Published As

Publication number Publication date
US20160018407A1 (en) 2016-01-21
GB201004994D0 (en) 2010-05-12
EP2411812B1 (en) 2013-10-02
US20120108668A1 (en) 2012-05-03
ES2432534T3 (es) 2013-12-04
GB2470803A (en) 2010-12-08
JP2012521551A (ja) 2012-09-13
WO2010109192A1 (en) 2010-09-30
EP2411812A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
JP5607719B2 (ja) 代謝プロファイル
Wen et al. Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study
JP7849400B2 (ja) 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
JP6392202B2 (ja) 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質
EP3028049B1 (en) Diagnostic tools for alzheimer's disease
JP2020521117A (ja) 診断用終末糖化産物抗体
Gao et al. Multiplex immuno-MALDI-TOF MS for targeted quantification of protein biomarkers and their proteoforms related to inflammation and renal dysfunction
WO2016124574A1 (en) Diagnostic tools for alzheimer's disease
Ruth et al. Analysis of membrane proteins from human chronic myelogenous leukemia cells: comparison of extraction methods for multidimensional LC− MS/MS
Becker et al. Contextualised urinary biomarker analysis facilitates diagnosis of paediatric obstructive sleep apnoea
CN113302702A (zh) 多路化测定及其使用方法
CN114026427A (zh) 诊断肾病的标志物以及诊断方法
EP4101465A1 (en) Determination agent and determination method for tauopathy and dementia-related diseases
CN112639476B (zh) 肾病变蛋白生物标记及其应用
Larimore et al. Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity
CN108318573B (zh) 检测胰岛素抵抗的质谱模型的制备方法
JP2011509408A (ja) 診断の方法を行うためのニトロ化タンパク質又はペプチド配列の使用
Fernández-Puente et al. Proteomic Profiling of Human Synovial Fluid Reveals AKR1C1 as a Biomarker of Osteoarthritis Severity
JP2021028573A (ja) 筋疾患の診断のためのバイオマーカー
Agarwal et al. Haematological and Metabolic Disturbances Induced by Chronic Unpredictable Stress in Albino Wistar Rats
US20170176434A1 (en) Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
JP2018163071A (ja) 関節リウマチに関するペプチドマーカー
WO2023102204A1 (en) Biomarker for type 1 diabetes
WO2022091793A1 (ja) 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発
BRAIN AMPA/QUISQUALATE RECEPTOR CAPABLE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140828

R150 Certificate of patent or registration of utility model

Ref document number: 5607719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees